Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel small-molecule therapies for psychiatric and central nervous system (CNS) disorders, including major depressive disorder, anxiety, substance use disorders, and schizophrenia. Founded in 2019 by Dr. Jonathan Sporn, Andrew Kruegel, and Dalibor Sames, the company designs and develops neuroplastogens and related compounds derived from psychedelic research that aim to deliver rapid-acting, durable therapeutic benefits while reducing or eliminating hallucinogenic effects. Its pipeline includes bretisilocin (GM-2505), a short-acting 5-HT2A receptor agonist (acquired by AbbVie in 2025), blixeprodil (GM-1020), an oral NMDA receptor antagonist, a cardio-safe ibogaine analog, and an M1/M4 agonist program. In May 2024 the company entered a collaboration and option-to-license agreement with AbbVie worth up to ~$2 billion (including $65M upfront), and in August 2025 AbbVie agreed to acquire bretisilocin in a deal valued at up to $1.2 billion (completed October 2025). Remaining assets and team were spun out into Gilgamesh Pharma Inc., which closed a $60M Series A in March 2026.
Gilgamesh Pharmaceuticals has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
11–50
Total Funding
$66M
2 rounds
Total raised $66M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
December 15, 2022
Amount
$39M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| December 15, 2022 | Series B | $39M | — | Prime Movers Lab |
| May 6, 2021 | Series A | $27M | — | Prime Movers Lab |
Jonathan Sporn
Founder, CEO & Chairman of the Board
Andrew Kruegel
Co-Founder
Dalibor Sames
Co-Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Compass Pathways
Clinical-stage mental health care company developing psilocybin-based therapies (COMP360) for treatment-resistant depression and PTSD.
atai Life Sciences
Biopharmaceutical platform developing psychedelic and consciousness-altering therapies for mental health disorders through multiple subsidiary programs.
Cybin
Clinical-stage biopharma developing psychedelic-based therapeutics including deuterated DMT (CYB003) for major depressive disorder.
MindMed
Clinical-stage biopharma developing LSD and other psychedelic-inspired therapies for anxiety and other psychiatric disorders.
Delix Therapeutics
Privately held neuroscience company developing non-hallucinogenic neuroplastogens for depression, anxiety, and addiction.
Perception Neuroscience
atai Life Sciences subsidiary developing arketamine (PCN-101) for treatment-resistant depression; previously founded by Gilgamesh CEO Jonathan Sporn.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.